Featured Trial

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Study Identifier:

405-201-00017

ClinicalTrials.gov Identifier:

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Recruiting

Therapeutic Area

ADHD

Study Drug

Drug: Centanafadine Hydrochloride

Estimated Enrollment

700

Phase

Phase 3

Type

Interventional

Trial Dates

Feb 2022 - Jan 2027

Study Locations

Location

Status

Location

For additional information regarding sites, contact 844-687-8522

New York, New York, United States, 10012

Status

N/A